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Results: In sodium-depleted marmosets, aliskiren (0.3–10 mg/kg p.o.) dose-dependently
inhibited renin and lowered MAP. After a single oral dose of 3 mg/kg aliskiren, MAP was
lowered maximally by 30±3 mmHg (n=6), and significant reductions in MAP persisted for
up to 24 h. At equivalent doses, aliskiren lowered MAP as effectively as the ACE inhibitor
benazepril and the AT1-receptor blocker valsartan, and more effectively than the previous
generation RIs, remikiren and zankiren. In SHR, aliskiren (10–100 mg/kg/day via s.c.
osmotic minipumps for 2 weeks) dose-dependently lowered MAP. Administration of sub-
maximally effective doses of aliskiren in combination with either benazeprilat or valsartan
strongly potentiated reductions in MAP. In human hypertensive patients, aliskiren (37.5,
75, 150 or 300 mg once daily for 4 weeks) also dose-dependently lowered BP and inhib-
ited renin. Aliskiren treatment was well tolerated at all doses, with BP reductions not
being accompanied by changes in heart rate, in marmosets, rats and humans.
Conclusions: Aliskiren provides 24 h blood pressure lowering with good tolerability in
sodium-depleted marmosets and human hypertensive patients after once-daily oral dos-
ing. Blockade of the RAS at source with aliskiren may therefore represent an effective,
novel approach to antihypertensive treatment both as monotherapy and in combination
with other RAS inhibitors.
1085-166 Does Hormone Replacement Therapy in Women 
Influence Their Benefit of Losartan-Treatment in the 
LIFE study?
Kristian Wachtell, Richard B. Devereux, Steven M. Snapinn, Michael H. Olsen, Ulf de 
Faire, Hans Ibsen, Stevo Julius, Sverre E. Kjeldsen, Lars H. Lindholm, Markku S. 
Nieminen, Björn Dahlöf, Glostrup University Hospital, Glostrup, Denmark, The Weill 
Medical College of Cornell University, New York, NY
Background: Effective drug treatment of hypertension has been shown to benefit
women, without consideration of concomitant hormone replacement therapy (HRT).This
analysis compared the effect of losartan relative to atenolol in women who were and
were not taking HRT.
Methods: As part of the LIFE study, in a double-blinded, randomized parallel group trial,
a total of 476 hypertensive women were taking HRT (HRT+) at baseline and 4,494 were
not taking HRT (HRT-) and followed for an average of 4.8 years.
Results: The composite endpoint of cardiovascular mortality, fatal and non-fatal stroke
and fatal and non-fatal myocardial infarction was similarly reduced in HRT- (11.2% with
atenolol-based treatment vs. 9.2% with losartan-based treatment, relative risk reduction
[RRR]=18.6%, p=0.037) and in HRT+ (7.5% with atenolol vs. 6.2% with losartan-based
treatment, RRR=12.6%, p=0.600). Test for interaction between HRT+ and HRT- losartan
vs. atenolol treatment was not significant for the composite endpoint (p=0.881). Similarly,
there were similar reductions in stroke with losartan compared to atenolol-based treat-
ment (6.9 vs. 4.5% in HRT- RRR=34.9%, p=0.001 and 3.3 vs. 3.8% in HRT+, RRR=-
27.2%, p=0.50), test for interaction p=0.105. Non-significant reductions in cardiovascular
mortality occurred with losartan-based treatment in both HRT- (3.93 vs. 4.3%,
RRR=10.3%, p=0.480) and HRT+ (2.1 vs. 3.5%, RRR=37.9%, p=0.24), Test for interac-
tion p=0.412). Similarly, there were non-significant reductions in fatal and non-fatal myo-
cardial infarction with losartan-based treatment compared to the atenolol treated group
(3.3 vs. 3.4% in HRG- RRR=-6.2%, p=0.73) and (2.7 vs. 1.9% in HRG+, RRR=27.6%,
p=0.46); test for interaction for myocardial infarction, p =0.461.
Conclusion: Losartan was superior to atenolol for reducing cardiovascular events
among women participating in the LIFE study. There is no evidence that this benefit dif-
fers according to whether or not the women were taking HRT.
1085-167 Dose-Response Study of the Efficacy and Safety of 
Fosinopril in Children With Hypertension: A 
Randomized, Double-Blind, Placebo-Controlled, 
Multicenter Clinical Trial
Jennifer S. Li, Katherine Y. Berezny, Rakhi Kilaru, Lydia Hazen, Ronald Portman, Ronald 
Hogg, Randall Jenkins, Prapti Kanani, Carol M. Cottril, Tej K. Mattoo, Ludmila Zharkova, 
Ludmila Kozlova, Irit Weisman, David Deitchman, Robert Califf, Duke Clinical Research 
Institute, Durham, NC
Background: Because the prevalence of childhood hypertension is increasing, there is a
growing need for data on using antihypertensive medications in children. This study eval-
uated the efficacy, safety, and dose-response relationship for fosinopril in children and
adolescents 6-16 years of age with hypertension or high-normal blood pressure with an
associated medical condition requiring treatment. 
Methods: The study was a prospective, double-blind, placebo-controlled, multicenter
trial conducted in 78 clinical sites in the US, Russia, and Israel. There were 4 study
phases: a screening phase of 10 days maximum, a 4-week dose-response phase, a pla-
cebo withdrawal phase of 2 weeks maximum, and a 52-week open-label safety phase.
The primary objective of the dose-response phase was to determine whether low (0.1
mg/kg), medium (0.3 mg/kg), or high (0.6 mg/kg) doses of fosinopril, which were based
on established adult dosing, affect trough seated systolic blood pressure (SBP). After the
dose-response phase, patients entered a double-blind randomized withdrawal and
received either fosinopril or placebo. This was followed by the open-label safety phase.
Adverse events were recorded throughout the entire study.
Results: During the dose-response phase, all 3 doses were equally effective in lowering
SBP. During the placebo withdrawal phase, there was an adjusted mean SBP increase of
5.2 mm Hg for the placebo group and 1.5 mm Hg for the fosinopril group, a net withdrawal
effect of 3.7 mm Hg (P = 0.013). Fosinopril was generally well-tolerated; serious adverse
events occurred infrequently and were generally not attributed to fosinopril.
Conclusion: Children ages 6-16 with hypertension or high-normal blood pressure with
concomitant illness or risk factors and treated with 0.1-0.6 mg/kg fosinopril once daily
had substantial mean decreases in SBP, yet no dose-response relationship was evident.
Withdrawal of fosinopril resulted in a statistically significant increase in SBP. Because
children appear to be more sensitive to lower doses of fosinopril than adults, fosinopril
starting doses for children should be < 0.1 mg/kg.
1085-170 Benefits of Losartan on Preventing Stroke in Patients 
With Isolated Systolic Hypertension: A LIFE Substudy
Sverre E. Kjeldsen, Bjorn Dahlof, Richard B. Devereux, Stevo Julius, Peter Aurup, 
Jonathan Edelman, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister 
Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per 
Omvik, Suzanne Oparil, Steven M. Snapinn, Hans Wedel, Paulette A. Lyle, The LIFE 
study group, Ullevaal University Hospital, Oslo, Norway, University of Michigan, Ann 
Arbor, MI
Stroke is now more common than myocardial infarction in hypertension. In a substudy of
the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study we tested
the hypothesis that a losartan-based regimen was more effective than an atenolol-based
regimen beyond blood pressure control in reducing cardiovascular (CV) morbidity and
mortality (composite CV death, stroke or myocardial infarction) in patients with ISH and
left ventricular hypertrophy (LVH) on electrocardiogram (ECG). Men and women (60%)
aged 55-80 (average 70) years with ISH (sitting blood pressure 160-200/<90 mmHg,
average 174/83 mmHg) and ECG-LVH were followed for a mean of 4.7 years. Blood
pressure was similarly reduced by 28.4/8.5 and 28.2/8.8 mmHg in the losartan (n=660)
and atenolol (n=666) arms, respectively. The primary composite endpoint was reduced
by 26% in the losartan group (25.1 per 1000 patient years) compared to the atenolol
group (35.8 per 1000 patient years; relative risk [RR] adjusted for Framingham risk score
and degree of ECG-LVH 0.74 [95% CI 0.55 – 1.00], p=0.051, unadjusted RR 0.70 [95%
CI 0.52 –0.94], p=0.019). Stroke data in this ISH group follow. (Three atenolol patients
had multiple stokes of different types. These patients are counted only once in the
patients with any stroke category.)
Consistent with LIFE primary results, these data suggest losartan-based treatment to be 
superior to atenolol-based treatment for patients with isolated systolic hypertension and 
high CV risk, especially for stroke.
1085-193 The Effect of Losartan Versus Atenolol on Hemostasis 
and Fibrinolysis in Hypertensive Patients With Left 
Ventricular Hypertrophy: A LIFE Substudy
Kurt O. Boman, Sr., Michael Hecht Olsen, Kristian Wachtell, Mona Olofsson, Hans Ibsen, 
Sr., Harriet Dige-Petersen, Torbjörn K. Nilsson, Sr., Umeå University, Skellefteå, Sweden
Background: In some studies treatment with angiotensin converting enzyme (ACE)
inhibitors seem to improve fibrinolysis. Our aim was to investigate the long-term effects of
an angiotensin II receptor blocker, losartan, on mass-concentrations of tissue plasmino-
gen activator (tPA), its inhibitor, PAI-1, tPA/PAI-1-complex, trombomodulin and von Wille-
brand factor (vWF) in patients with hypertension and left ventricular hypertrophy.
Methods: In 44 patients recruited for the LIFE Study with stage II-III hypertension and
ECG left ventricular hypertrophy we measured tPA, PAI-1, tPA/PAI complex, trombomod-
ulin, and von Willebrand factor (vWf) at baseline, after one and five years of anti-hyper-
tensive treatment with either an atenolol- or a losartan-based regime.
Results: Plasma levels of tPA (10.5 vs. 8.8µg/l, p=0.01), PAI-1 (31,6 vs. 8,4 µg/l, p=0.002
tPA/PAI-1 complex (7.6 vs. 4.8µg/l, p=0.03) and trombomodulin (10.6 vs. 8.4µg/l, p=0.06)
were reduced during five years of losartan-based antihypertensive treatment, whereas
PAI-1 (24,4 vs. 11,4µg/l, p=0.036) and vWF (175 vs. 174%, p=0.05) was reduced in
patients treated with atenolol-based antihypertensive treatment. Comparing the two
treatments, there were no significant differences in plasma tPA, PAI-1, and vWF at base-
line, after one and five years of antihypertensive treatment. However, after five years of
treatment, plasma levels of tPA/PAI-1 complex (4.8 vs. 6.8µg/l, p=0.02) and trombomodu-
lin (8.4 vs. 11.8µg/l, p=0.01) were significantly lower in patients treated with losartan.
Conclusion: In hypertensive patients with left ventricular hypertrophy losartan seemed
to have a beneficial time-dependent effect on the fibrinolytic system and the plasma level
of trombomodulin compared to treatment with atenolol.
1085-194 Eplerenone Improves Coronary Hemodynamics and 
Reduces Cardiac Fibrosis in Aging Spontaneously 
Hypertensive Rats
Dinko Susic, Jasmina Varagic, Iwari Ahn, Louis Matavelli, Edward D. Frohlich, Ochsner 
Clinic Foundation, New Orleans, LA
Background: Aldosterone is considered to be involved in development of age- and hyper-
tension-related cardiac fibrosis and its consequences such as impaired coronary hemo-
dynamics. Thus, the effects of an aldosterone antagonist, eplerenone (E), on
cardiovascular mass, myocardial collagen, and coronary circulation were examined in
spontanously hypertensive rats.
Methods. Male, 22-week old rats were randomly divided into two groups (30 rats in each).
The control group did not receive any treatment, the second group was given E (mixed in
Losartan
n=660
Atenolol
n=666
Adjusted RR
(95% CI)
p-value
Patients with any stroke 32 (4.8%) 56 (8.4%) 0.60 (0.38-0.92) 0.020
Fatal stroke 4 (0.6%) 14 (2.1%) 0.30 (0.10-0.92) 0.035
Atherothrombotic stroke 22 (3.3%) 42 (6.3%) 0.55 (0.32-0.92) 0.022
Embolic stroke 8 (1.2%) 13 (2.0%) 0.64 (0.26-1.56) 0.33
Hemorrhagic or other stroke 2 (0.3%) 4 (0.6%) Too few events
